Â鶹Éç

Occasionally, growth hormone (GH) deficiency is diagnosed in the evaluation of poorly growing children which can be treated with recombinant GH injections. We aim to measure circulating bone markers in a large group of healthy children and adolescents to establish reference ranges in relation to linear growth and pubertal timing. We further aim to measure bone markers in children prior to- and during treatment with GH to potentially individualize GH dosing, and hereby improve treatment control.